HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Georgy, A. Articles by Goodin, S. Search for Related Content PubMed PubMed Citation Articles by Georgy, A. Articles by Goodin, S.

ANGELA GEORGY, PHARM.D., is Fellow, Pharmaceutical Industry Fellowship Institute, School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway. JACALYN NECESKAS, PHARM.D., is Oncology Pharmacist, Division of Pharmaceutical Sciences, The Cancer Institute of New Jersey (CINJ), New Brunswick, NJ. SUSAN GOODIN, PHARM.D., is Director, Division of Pharmaceutical Sciences, CINJ, and Associate Professor of Medicine, Division of Medical Oncology, Robert Wood Johnson Medical School University of Medicine and Dentistry of New Jersey, New Brunswick.

Address correspondence to Dr. Goodin at the Division of Pharmaceutical Sciences, The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901-1914 (goodin{at}umdnj.edu).

Purpose. The drug interactions and adverse events that should be considered when individualizing antiemetic therapy for patients undergoing treatment for breast cancer are reviewed. Summary. A variety of antiemetic agents are available, including antihistamines, dopamine-receptor antagonists, serotonin-receptor antagonists, and neurokinin-receptor antagonists. To ensure optimal symptom control for each patient without unnecessarily prolonging treatment, patient- and treatment-specific risk factors must be considered. Neurokinin-receptor antagonists, the newest class of antiemetics, are effective in preventing acute and delayed chemotherapy-induced nausea and vomiting but must be used in combination with a serotonin-receptor antagonist and a corticosteroid. The serotonin-receptor antagonists have become the mainstay of antiemetic therapy, but current guidelines do not distinguish among the different agents in this class. However, there are distinct pharmacologic differences that may affect the potential for drug interactions and, ultimately, patient outcomes and the occurrence of adverse events. Therefore, the potential for drug interactions must be considered when selecting an antiemetic, particularly for patients who are taking multiple concomitant medications. Further, because a number of breast cancer therapies and some antiemetic agents carry cardiovascular warnings or precautions and since breast cancer patients may already be suffering from cardiovascular complications, the possible cardiotoxic effects of the antiemetic or chemotherapy agents or the combinations of these agents should be considered. Conclusion. Antiemetic treatment is essential for patients with breast cancer who are undergoing moderately to highly emetogenic cytotoxic treatment. When selecting an antiemetic, clinicians must select an agent that provides optimal protection against nausea and vomiting while avoiding drug–drug interactions and additional adverse events. Index terms: Antiemetics; Antineoplastic agents; Breast neoplasms; Combined therapy; Drug interactions; Drugs; Mechanism of action; Nausea; Steroids, cortico-; Toxicity